AUTHORS
Enoc Granados Granados Centeno, BSc, Kyra Bergerud2, Qianyun Luo, BS3, Lynn M Heltemes Harris, PhD4, Michael Farrar, PhD5, Sean I. Tracy, MD, PhD6
AFFILIATIONS
1 University of Minnesota, Minneapolis, Minnesota, United States
2 University of Minnesota, Minneapolis, Minnesota, United States
3 University of Minnesota, Minneapolis, Minnesota, United States
4 University of Minnesota, Minneapolis, Minnesota, United States
5 University of Minnesota, Minneapolis, Minnesota, United States
6 University of Minnesota, Minneapolis, Minnesota, United States, University of Minnesota, Minneapolis, Minnesota, United States
ABSTRACT
Background: At diagnosis, the B-ALL microenvironment is paradoxically enriched with both immunosuppressive myeloid cells and activated, leukemia-specific CD8+ T-cells. The mechanisms underlying the coexistence of these cell types remain largely unknown, although CD4+ T-cells likely govern their balance. CD4+ T-cell subsets promote CD8+ T-cell activation via licensing of cDC1s, while also shaping local myeloid composition through direct cytotoxicity, checkpoint engagement, and IL-10 signaling. The transcription factor Eomesodermin (Eomes) was recently shown to regulate CD4+ T-cell subset differentiation in multiple blood cancers, suggesting that Eomes-driven CD4+ T-cell heterogeneity shapes the leukemic bone marrow microenvironment. Here, we used a murine model of CD4+ T-cell-dependent immunity in BCR-ABL+ B-ALL to determine how distinct Eomes-expressing CD4+ subsets influence CD8+ T-cell activation and immunosuppressive myeloid activity during leukemia initiation.
Methods: HV1 mice express a fixed T-cell receptor on CD4+ T cells that recognizes a neoantigenic peptide within BCR-ABL. HV1-IL10-GFP reporter cells (30,000 cells/mouse) were transferred into C57BL/6 mice 24h prior to transfer of the BCR-ABL+ B-ALL cell line LM138 (7,500 cells/mouse). Recipients were sacrificed at days 3, 5, 7, and 10. The composition, phenotype, and spatial organization of cell types in the femur and spleen were profiled using flow cytometry paired with 28-plex spatial proteomic imaging (CellScape, Bruker). Cells were segmented (Cellpose 4) and classified via marker-based gating and hierarchical clustering (FlowSOM).
Results: Leukemia-specific CD4+ T cells (HV1s) localized to the femur and spleen and were activated in the spleen at day 3 (>95% CD44hi). Splenic HV1–cDC1–CD8 cross-priming immune triads peaked at day 5 before declining by day 10, coinciding with progressive loss of surface CD40L on HV1s. Between days 3 and 10, the frequency of cDC1s decreased (38% of CD11c+ cells at day 3 vs. 29% at day 10) while cDC2s reciprocally increased (24% at day 3 vs. 60% at day 10; p<0.05, binomial test, for both subsets). CellCharter identified canonical splenic spatial domains including the marginal zone, B-cell follicle, and PALS, plus two non-canonical domains both localized to the red pulp. LM138-centered neighborhood analysis (KD-tree-based, 50 μm radius) revealed significant enrichment of HV1s, GzmB+ NK cells, and cDC1s within the red pulp (all p<0.001 by permutation testing, n = 10,000), with M2 macrophages also significantly enriched (p = 0.003); spatial KDE density maps corroborated these findings.
Of the two non-canonical red pulp domains identified by CellCharter, the first was characterized by the close proximity (20 μm median) of IL10lo/TIM3- HV1s with apoptotic (cleaved caspase-3+) myeloid cells, suggesting HV1-mediated killing; by paired flow cytometry, these HV1s expressed Tfh markers alongside high levels of Eomes. The second domain was instead dominated by unchecked leukemic expansion and enrichment of IL10hi/TIM3+ HV1s expressing moderate Eomes and Th markers. Regardless of activation state, CD8+ T cells largely remained outside typical cytotoxic synapse range of LM138 cells across all red pulp domains (median distance 49.7 μm, IQR 27.8–92.3 μm), suggestive of spatial exclusion.
Conclusion: Our findings suggest that the red pulp of the spleen is an important anatomical site for training the emerging leukemia-specific T-cell response. In the spleen, functionally distinct CD4+ T-cell programs appear to operate simultaneously, leading to activation of CD8+ T-cells at early timepoints, but progressive reshaping of myeloid cell populations towards immunosuppressive states during leukemia progression. These actions are divergently shaped by Eomes-hi/IL10lo/Tfh+ and Eomes-med/IL10hi/Th+ HV1 cell subsets that are spatially localized to at least two discrete red pulp domains, one linked to myeloid cell apoptosis, and the other to unchecked leukemia outgrowth. The decline in HV1-cDC1-CD8 immune triads alongside emergence of these spatial domains suggests a temporal shift in antigen presentation, which likely shapes divergent CD4+ T-cell trajectories. These findings support further investigation of Eomes-defined CD4+ subsets and their spatial relationships to myeloid and CD8+ populations as biomarkers of immune microenvironment quality, and as therapeutic targets for shifting local immunity toward productive anti-leukemic responses.
DISCLOSURES
Sean I. Tracy, MD, PhD: No relevant conflicts of interest to declare.